Barry A. Springer
13Patents
6h-index
30Co-inventors
62Inventor score
Filing activity: Dec 23, 1998 → Aug 17, 2016
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6569631B1 | Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes | Physics | 222 | Expired |
| US6268158A | Method for determining conditions that facilitate protein crystallization | Emerging Cross-Sectional Technologies | 39 | Expired |
| US6274712A | Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137 | Human Necessities | 29 | Expired |
| US6232085A | Method for determining conditions that stabilize proteins | Emerging Cross-Sectional Technologies | 15 | Expired |
| US6291192A | Method for identifying conditions that facilitate recombinant protein folding | Emerging Cross-Sectional Technologies | 14 | Expired |
| US6291191A | Microplate thermal shift assay for ligand development and multi-variable protein chemistry optimization | Emerging Cross-Sectional Technologies | 7 | Expired |
| US6737404B2 | Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137 | Human Necessities | 4 | Expired |
| US8883473B2 | Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases | Physics | 1 | Active |
| US8798939B2 | Methods for designing, selecting and/or optimizing allosteric processing inhibitors for matrix metalloproteinases | Emerging Cross-Sectional Technologies | 0 | Active |
| US9815790B2 | Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists | Chemistry; Metallurgy | 0 | Active |
| US8753857B2 | Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor | Chemistry; Metallurgy | 0 | Active |
| US7138374B2 | Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, asparate 101 or leucine 137 | Human Necessities | 0 | Expired |
| US6767722B1 | Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, Aspartate 101 or Leucine 137 | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.